Leflunomide

What is Leflunomide?

Leflunomide is a pharmaceutical compound classified as a disease-modifying antirheumatic drug (DMARD). It is primarily used in the management of autoimmune conditions, particularly those affecting the joints. As an immunosuppressant, Leflunomide works by modulating the immune system to reduce inflammation and prevent progressive joint damage associated with chronic autoimmune diseases.

Belonging to the ATC code I01, which encompasses immunosuppressants, Leflunomide plays a crucial role in long-term disease management. Its therapeutic effects are not immediate and typically require several weeks to months of consistent administration to become fully apparent, aiming to slow disease progression and improve quality of life by reducing pain, swelling, and stiffness.

Mechanism of Action

Leflunomide functions as a prodrug, metabolized in the body to its active metabolite, teriflunomide. Teriflunomide is responsible for the drug's therapeutic effects, primarily involving the inhibition of dihydroorotate dehydrogenase (DHODH), a crucial mitochondrial enzyme.

• Inhibits Dihydroorotate Dehydrogenase (DHODH): Teriflunomide reversibly inhibits DHODH, an enzyme essential for the de novo synthesis of pyrimidine nucleotides.
• Blocks De Novo Pyrimidine Synthesis: By blocking DHODH, the active metabolite effectively starves rapidly proliferating cells, such as activated T-lymphocytes, of the necessary building blocks for DNA and RNA synthesis.
• Prevents Proliferation of Activated T-lymphocytes: Activated lymphocytes, which are key drivers of inflammation and tissue damage in autoimmune diseases, are particularly dependent on de novo pyrimidine synthesis for their rapid expansion. By inhibiting this pathway, Leflunomide reduces their proliferation.
• Reduces Inflammation and Joint Damage: The resulting decrease in the number and activity of pathogenic immune cells helps to suppress the autoimmune response, thereby reducing inflammation, pain, and preventing further structural damage to joints.

Medical Uses

Leflunomide is a valuable treatment option for chronic inflammatory autoimmune diseases where immune system overactivity leads to tissue damage.

Primary Uses

• Rheumatoid Arthritis (RA): Leflunomide is widely used to reduce the signs and symptoms of RA, slow the progression of structural damage, and improve physical function in adult patients.
• Psoriatic Arthritis (PsA): It is also indicated for the treatment of active psoriatic arthritis, helping to alleviate joint inflammation and skin symptoms associated with the condition.

Secondary Uses (Off-label or Investigational)

• Other Autoimmune Conditions: Due to its immunosuppressive properties, Leflunomide has been explored, sometimes off-label, in the treatment of other autoimmune disorders where immune modulation is beneficial, such as systemic lupus erythematosus or certain forms of vasculitis.

Dosage

The dosage of Leflunomide is carefully determined by a healthcare professional based on the specific indication, patient response, and tolerability. It is administered orally, typically once daily. A loading dose may be used to achieve therapeutic levels more quickly in some cases.

Side Effects

Like all medications, Leflunomide can cause side effects, ranging from mild to severe. Patients should discuss potential side effects with their doctor and report any concerning symptoms promptly. Regular monitoring, particularly of liver function and blood counts, is essential during treatment.

Common Side Effects (may affect more than 1 in 10 people)

• Diarrhea
• Nausea or abdominal pain
• Hair thinning or loss (alopecia)
• Skin rash
• Elevated liver enzymes (transaminases)
• Hypertension (high blood pressure)
• Headache
• Dizziness

Rare but Serious Side Effects (may affect up to 1 in 1,000 people or less)

• Severe liver damage or failure
• Interstitial lung disease (ILD)
• Bone marrow suppression (leading to anemia, leukopenia, or thrombocytopenia)
• Peripheral neuropathy (nerve damage)
• Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Increased risk of serious infections
• Pancreatitis

Warnings

Leflunomide carries several important warnings and contraindications due to its potent immunosuppressive and potential toxic effects. It is crucial for patients to be thoroughly evaluated before starting treatment and to adhere strictly to medical advice during therapy.

Contraindications

• Pregnancy and Breastfeeding: Leflunomide is highly teratogenic (causes birth defects) and must not be used during pregnancy. Women of childbearing potential must use effective contraception. It is also contraindicated in breastfeeding mothers.
• Severe Liver Disease: Patients with pre-existing severe liver impairment are at increased risk of hepatotoxicity.
• Severe Immunodeficiency States: Conditions such as AIDS or other severe immunodeficiency states can be exacerbated.
• Uncontrolled Infections: Active, severe infections should be resolved before initiating Leflunomide.
• Severe Bone Marrow Dysplasia: Patients with significant bone marrow suppression or severe anemia, leukopenia, or thrombocytopenia should avoid this drug.
• Known Hypersensitivity: Allergy to Leflunomide or its active metabolite, teriflunomide.

Disclaimer: This article provides general medical information and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment.